ILS Clinical Research   Report issue

For profit Phase 2 Phase 3
Founded: Mexico City Mexico (2015)

Organization Overview

First Clinical Trial
2018
NCT03460743
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

ILS Clinical Research

Active Ingredients

Drugs in Phase 3 Trials (1)

inactivated influenza vaccine (1 trial)

Drugs in Phase 2 Trials (1)

atezolizumab (Tecentriq) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 3)

Mesothelioma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2